Evidence map›Paper›PMID 39173830›Full record

ArticleSLAS discovery : advancing life sciences R & D2024

SARS-CoV-2 M

Renee Delgado, Jyoti Vishwakarma, Seyed Arad Moghadasi, Yuka Otsuka, Justin Shumate, Ashley Cuell, Megan Tansiongco, Christina B Cooley, Yanjun Chen, Agnieszka Dabrowska and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. A Novel Fluorescence Polarization Binding Assay for the Main Protease (MACS pharmacology & translational science · 2025
    Article
  3. High throughput screening for SARS-CoV-2 inhibitors targeting 5 helix bundle.SLAS discovery : advancing life sciences R & D · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Renee DelgadoDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Jyoti VishwakarmaDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Seyed Arad MoghadasiDepartment of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA; Department of Biochemistry & Molecular Pharmacology, New York University School of Medicine, New York, NY 10016, USA.
Yuka OtsukaDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Justin ShumateDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Ashley CuellDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Megan TansiongcoDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA; Department of Chemistry, Trinity University, San Antonio, TX 78212, USA.
Christina B CooleyDepartment of Chemistry, Trinity University, San Antonio, TX 78212, USA.
Yanjun ChenDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Agnieszka DabrowskaDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Rahul BasuDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA.
Paulina Duhita AninditaLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore; Institute of Structural Biology, Nanyang Technological University, Singapore, 639798, Singapore.
Dahai LuoLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 308232, Singapore; Institute of Structural Biology, Nanyang Technological University, Singapore, 639798, Singapore.
Peter I DosaDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.
Daniel A HarkiDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA.
Thomas BannisterDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Louis ScampaviaDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Timothy P SpicerDepartment of Molecular Medicine, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL 33458, USA.
Reuben S HarrisDepartment of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA; Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Electronic address: rsh@uthscsa.edu.

Funding

Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Donghoon Chung · 2022 to 2026
$100.9M
Tandem Multi-modal Plate Readers for a High Throughput Screening platformS10OD030330 · OD · UNIVERSITY OF FLORIDA · PI SCAMPAVIA, LOUIS DANIEL · 2021 to 2021
$600k
Howard Hughes Medical InstituteNIAID NIH HHS U19 AI171954NIH HHS S10 OD030330
6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2, SARS2) is responsible for the COVID-19 pandemic and infections that continue to affect the lives of millions of people worldwide, especially those who are older and/or immunocompromised. The SARS2 main protease enzyme, M

Indexed as

Antiviral AgentsCoronavirus 3C ProteasesHigh-Throughput Screening AssaysSARS-CoV-2COVID-19COVID-19 Drug TreatmentDrug DiscoveryHumansProtease InhibitorsSmall Molecule Libraries3C-like proteinase, SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesProtease InhibitorsSmall Molecule LibrariesAntiviral drugscell-based ultra-high throughput screening (uHTS)protease inhibitorsSARS-CoV-2 main protease (M(pro)/3CL(pro))

Identifiers

PMID39173830
PMCPMC11550483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.